From: Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
Response
Ce-SOX
SOX
P
Complete response
1
0
-
Partial response
16
11
0.11
Stable disease
10
8
0.18
Progressive disease
4
6
0.15
Response rate (%)
54.8
44.0
0.22
Disease control rate (%)
87.1
76.0
0.16